July 27, 2020
According to the research report titles ‘Global Hydroxychloroquine Sulfate Tablets Market Size study, by Grade (USP Standards Grade, EP Standards Grade, Pharmaceutical Standard Grade and Others), by Application (Malaria, Arthritis, Skin Lesions, Lupus, COVID 19 and Others) and Regional Forecasts 2020-2026’, available with Market Study Report LLC, global hydroxychloroquine sulfate tablets market is projected to witness tremendous growth during 2020-2026.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2633135/
Based on grade, the market is segmented into USP, pharmaceutical, EP, and other standard grade. With respect to the application spectrum, the industry is divided into malaria, arthritis, lupus, skin lesions, COVID-19, and others.
As per regional overview, global hydroxychloroquine sulfate tablets industry is segmented into North America, Asia Pacific, Europe, Latin America and Rest of the World. Asia Pacific market is expected to witness substantial growth over the forecast period, due to the presence of major players in the region. Favorable initiatives by the government is expected to contribute to hydroxychloroquine sulfate tablets market share in APAC.
Leading players in global hydroxychloroquine sulfate tablets market include Teva Pharmaceutical Industries Ltd., Zydus Cadila, Ipca Laboratories Ltd., Abbott Laboratories, Novartis AG, Bayer AG, Abcam plc, Rising Pharma Holdings Inc., and Mylan N.V. among others.